日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:

Subtyping Alzheimer's disease and Parkinson's disease using longitudinal electronic health records

利用纵向电子健康记录对阿尔茨海默病和帕金森病进行亚型分类

Lian, Jie; Fan, Zhengxian; Petrazzini, Ben Omega; Fan, Wei; Rao, Shishir; Yang, Qianqian; Zeng, Guyu; Ahmed, Nouman; Tabassi Mofrad, Fatemeh; Wamil, Malgorzata; Rahimi, Kazem

Reframing obesity-related HFpEF as a multiorgan syndrome: incretin-based therapies and imaging endpoints

将肥胖相关的HFpEF重新定义为多器官综合征:基于肠促胰素的疗法和影像学终点

Mahmod, Masliza; Dennis, Andrea; Lian, Jie; Langford, Caitlin; Rahimi, Kazem; Wamil, Malgorzata

Phase 3b Extension Study MT-1186-A04 to Evaluate the Continued Efficacy and Safety of Edaravone Oral Suspension for Up to an Additional 48 Weeks in Patients With Amyotrophic Lateral Sclerosis

MT-1186-A04 3b 期扩展研究旨在评估依达拉奉口服混悬液在肌萎缩侧索硬化症患者中持续 48 周的疗效和安全性

Genge, Angela; Rothstein, Jeffrey; De Silva, Shari; Zinman, Lorne; Chum, Marvin; Chiò, Adriano; Sobue, Gen; Aoki, Masashi; Yoshino, Hiide; Doyu, Manabu; Selness, Daniel; Todorovic, Vesna; Hirai, Manabu; Sasson, Nissim; Takahashi, Fumihiro; Cecić, Michelle; Wamil, Art; Apple, Stephen

Refined selection of individuals for preventive cardiovascular disease treatment with a transformer-based risk model

利用基于Transformer的风险模型,对预防性心血管疾病治疗的个体进行更精准的选择。

Rao, Shishir; Li, Yikuan; Mamouei, Mohammad; Salimi-Khorshidi, Gholamreza; Wamil, Malgorzata; Nazarzadeh, Milad; Yau, Christopher; Collins, Gary S; Jackson, Rod; Vickers, Andrew; Danaei, Goodarz; Rahimi, Kazem

Redefining endpoints in heart failure clinical trials: the emerging role of wearable technologies in contemporary trial design

重新定义心力衰竭临床试验的终点:可穿戴技术在当代试验设计中的新兴作用

Alawoad, Zahra; Jensen, Jesper; Schou, Morten; Ahmed, Nouman; Attia, Abdelrahman; Rao, Shishir; Rahimi, Kazem; Wamil, Malgorzata

Targeting Cardiac Metabolism in Heart Failure with PPARα Agonists: A Review of Preclinical and Clinical Evidence

利用PPARα激动剂靶向治疗心力衰竭中的心脏代谢:临床前和临床证据综述

Handford, Carla; Stirling-Barros, Laura; Ganji-Arjenaki, Mahboube; Mahmod, Masliza; Nazarzadeh, Milad; Wamil, Malgorzata

Efficacy and Safety of Once Daily Dosing vs. Approved On/Off Dosing of Edaravone Oral Suspension Up to 48 Weeks in Patients With Amyotrophic Lateral Sclerosis (Study MT-1186-A02)

肌萎缩侧索硬化症患者每日一次给药与批准的间歇性给药方案(依达拉奉口服混悬液)长达 48 周的疗效和安全性比较(MT-1186-A02 研究)

Rothstein, Jeffrey; Genge, Angela; De Silva, Shari; Zinman, Lorne; Chum, Marvin; Chio, Adriano; Sobue, Gen; Aoki, Masashi; Yoshino, Hiide; Doyu, Manabu; Selness, Daniel; Todorovic, Vesna; Sasson, Nissim; Hirai, Manabu; Takahashi, Fumihiro; Salah, Alejandro; Wamil, Art; Apple, Stephen

Safety Extension Study of Edaravone Oral Suspension in Patients With Amyotrophic Lateral Sclerosis for up to an Additional 96 Weeks of Treatment

一项针对肌萎缩侧索硬化症患者的依达拉奉口服混悬液安全性扩展研究,疗程最长可达96周

Genge, Angela; Pattee, Gary L; Sobue, Gen; Aoki, Masashi; Yoshino, Hiide; Couratier, Philippe; Lunetta, Christian; Petri, Susanne; Selness, Daniel; Todorovic, Vesna; Sasson, Nissim; Hirai, Manabu; Takahashi, Fumihiro; Salah, Alejandro; Apple, Stephen; Wamil, Art; Kalin, Alexander; Jackson, Carlayne E

Analysis of Long-Term Function and Survival of Edaravone Oral Suspension-Treated Patients With Amyotrophic Lateral Sclerosis Using PRO-ACT Data as Historical Placebo Controls

利用 PRO-ACT 数据作为历史安慰剂对照,分析依达拉奉口服混悬液治疗肌萎缩侧索硬化症患者的长期功能和生存情况

Takahashi, Fumihiro; Genge, Angela; Hirai, Manabu; Selness, Daniel; Todorovic, Vesna; Wamil, Art; Sasson, Nissim; Apple, Stephen; Ushirogawa, Yoshiteru

Editorial: Advances in multi-modality imaging for precision medicine in cardiomyopathies

社论:多模态成像在心肌病精准医疗中的应用进展

Wamil, Malgorzata; Androulakis, Emmanuel